Paul G. Corn

14.7k total citations · 2 hit papers
190 papers, 8.2k citations indexed

About

Paul G. Corn is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Paul G. Corn has authored 190 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Pulmonary and Respiratory Medicine, 74 papers in Oncology and 65 papers in Cancer Research. Recurrent topics in Paul G. Corn's work include Prostate Cancer Treatment and Research (90 papers), Renal cell carcinoma treatment (42 papers) and Cancer Genomics and Diagnostics (39 papers). Paul G. Corn is often cited by papers focused on Prostate Cancer Treatment and Research (90 papers), Renal cell carcinoma treatment (42 papers) and Cancer Genomics and Diagnostics (39 papers). Paul G. Corn collaborates with scholars based in United States, Spain and United Kingdom. Paul G. Corn's co-authors include James G. Herman, Manel Esteller, Stephen B. Baylin, Timothy C. Thompson, Theodoros Karantanos, Christopher J. Logothetis, S B Baylin, Nizar M. Tannir, Ana M. Aparicio and Eric Jonasch and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Nature Genetics.

In The Last Decade

Paul G. Corn

176 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A gene hypermethylation profile of human cancer.

2001 1.7k citations Paul G. Corn et al. profile →
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

2013 634 citations Paul G. Corn, Timothy C. Thompson et al. Oncogene profile →

Peers

Countries citing papers authored by Paul G. Corn

Since Specialization

Citations

This map shows the geographic impact of Paul G. Corn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul G. Corn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul G. Corn more than expected).

Fields of papers citing papers by Paul G. Corn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul G. Corn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul G. Corn. The network helps show where Paul G. Corn may publish in the future.

Co-authorship network of co-authors of Paul G. Corn

This figure shows the co-authorship network connecting the top 25 collaborators of Paul G. Corn. A scholar is included among the top collaborators of Paul G. Corn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul G. Corn. Paul G. Corn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA94 LenCabo: A randomized phase II multicenter trial of lenvatinib plus everolimus (len/eve) versus (vs) cabozantinib (cabo) in patients (pts) with metastatic clear cell RCC (ccRCC) that progressed on PD-1 immune checkpoint inhibition (ICI) 2025 ·Annals of Oncology ·Andrew W. Hahn, Jad Chahoud, William Paul Skelton, (unknown), Amado J. Zurita, (unknown), Omar Alhalabi, Matthew T. Campbell, Eric Jonasch, John K. Lin, (unknown), Hye Jin Hwang, Paul G. Corn, Pavlos Msaouel, Nizar M. Tannir	0
2	A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo) 2025 ·Annals of Oncology ·Andrew W. Hahn, Jad Chahoud, William Paul Skelton, Ying Yuan, Amado J. Zurita, (unknown), Omar Alhalabi, Matthew T. Campbell, Eric Jonasch, John K. Lin, (unknown), (unknown), Hyunsoo Hwang, Paul G. Corn, Pavlos Msaouel, Nizar M. Tannir	0
3	Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153). 2024 ·Journal of Clinical Oncology ·Christos E. Kyriakopoulos, Yu‐Hui Chen, Robert Jeraj, Fenghai Duan, Jun Luo, Emmanuel S. Antonarakis, Abhishek Tripathi, David Kosoff, Rohan Garje, Russell K. Pachynski, Rahul Atul Parikh, Andrea Harzstark, Nabil Adra, Benjamin L. Maughan, Yousef Zakharia, Paul G. Corn, Glenn Liu, Michael A. Carducci	2
4	Prognostic factors of relapse in surgically resected small cell neuroendocrine carcinomas of the urothelial tract (SCNEC-URO). 2024 ·Journal of Clinical Oncology ·(unknown), Nathaniel R. Wilson, Lianchun Xiao, (unknown), Jianjun Gao, Amishi Y. Shah, Paul G. Corn, Sangeeta Goswami, Pavlos Msaouel, Nizar M. Tannir, Byron Lee, Ashish M. Kamat, Mehrad Adibi, Colin P. Dinney, Donna E. Hansel, Charles C. Guo, Arlene O. Siefker‐Radtke, Matthew T. Campbell, Omar Alhalabi	1
5	Body composition in recurrent prostate cancer and the role of steroidogenic genotype 2024 ·Endocrine Related Cancer ·(unknown), Rebecca S. Tidwell, Yao Yu, (unknown), Amado J. Zurita, Sumit K. Subudhi, Bilal A. Siddiqui, (unknown), Justin R. Gregg, Paul G. Corn, Efstratios Koutroumpakis, Jennifer L. McQuade, Daniel E. Frigo, Patrick G. Pilié, Chad D. Huff, (unknown), Andrew W. Hahn	0
6	Radium-223 Treatment Produces Prolonged Suppression of Resident Osteoblasts and Decreased Bone Mineral Density in Trabecular Bone in Osteoblast Reporter Mice 2024 ·Cancers ·Song-Chang Lin, Guoyu Yu, Paul G. Corn, Jossana A. Damasco, Yu‐Chen Lee, Jian H. Song, Nora M. Navone, Christopher J. Logothetis, Marites P. Melancon, Theocharis Panaretakis, Sue-Hwa Lin	0
7	Polyploid cancer cells reveal signatures of chemotherapy resistance 2024 ·Oncogene ·J. Michael Schmidt, (unknown), Rishvanth K. Prabakar, Mohamed Kamal, (unknown), Isla P. Garraway, Michael Lewis, (unknown), Amado J. Zurita, Paul G. Corn, Peter Kühn, Kenneth J. Pienta, Sarah R. Amend, James Hicks	10
8	Prostate cancer–induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone–tumor microenvironment through Wnt pathway–induced M2 macrophage polarization 2024 ·Proceedings of the National Academy of Sciences ·Guoyu Yu, Paul G. Corn, (unknown), Xin Liang, Miao Zhang, Patricia Troncoso, Jian H. Song, Song-Chang Lin, Xingzhi Song, Jingjing Liu, Jianhua Zhang, Christopher J. Logothetis, Marites P. Melancon, Theocharis Panaretakis, Guocan Wang, Sue-Hwa Lin	9
9	SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression 2023 ·Clinical Cancer Research ·(unknown), (unknown), Ganiraju C. Manyam, Jody V. Vykoukal, Johannes F. Fahrmann, Shan Peng, Cheng Wu, (unknown), Shakuntala Kondraganti, Daoqi Wang, Brian D. Robinson, Massimo Loda, Christopher E. Barbieri, Timothy A. Yap, Paul G. Corn, Samir Hanash, Bradley M. Broom, Patrick G. Pilié, Timothy C. Thompson	11
10	Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition 2022 ·Cancer Research ·Guoyu Yu, Paul G. Corn, Pengfei Shen, Jian H. Song, Yu‐Chen Lee, Song-Chang Lin, Jing Pan, Sandeep K. Agarwal, Theocharis Panaretakis, Maurizio Pacifici, Christopher J. Logothetis, Li‐Yuan Yu‐Lee, Sue-Hwa Lin	13
11	ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer 2021 ·Clinical Cancer Research ·Zhe Tang, Patrick G. Pilié, Chuandong Geng, Ganiraju C. Manyam, Guang Yang, Sanghee Park, Daoqi Wang, Shan Peng, Cheng Wu, Guang Peng, Timothy A. Yap, Paul G. Corn, Bradley M. Broom, Timothy C. Thompson	97
12	Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer 2021 ·European Journal of Cancer ·(unknown), (unknown), (unknown), John W. Davis, Amado J. Zurita, Xuemei Wang, Shi‐Ming Tu, Brian F. Chapin, Ana M. Aparicio, Paul G. Corn, Jennifer Wang, Sumit K. Subudhi, John C. Araujo, John Papadopoulos, (unknown), (unknown), Christopher J. Logothetis, Eleni Efstathiou	12
13	Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer 2020 ·Clinical Cancer Research ·Paymaneh D. Malihi, Ryon P. Graf, Ángel Rodríguez, Naveen Ramesh, Jerry Lee, (unknown), (unknown), Carmen Ruiz Velasco, Emi Sei, Anand Kolatkar, Christopher J. Logothetis, Nicholas E. Navin, Paul G. Corn, Ana M. Aparicio, Ryan Dittamore, James Hicks, Peter Kühn, Amado J. Zurita	61
14	Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer 2020 ·Science Translational Medicine ·Sumit K. Subudhi, Luis M. Vence, Hao Zhao, Jorge Blando, Shalini S. Yadav, Qing Xiong, Alexandre Reuben, Ana M. Aparicio, Paul G. Corn, Brian F. Chapin, Louis L. Pisters, Patricia Troncoso, Rebecca S. Tidwell, Peter F. Thall, Chang‐Jiun Wu, Jianhua Zhang, (unknown), P. Andrew Futreal, James P. Allison, Padmanee Sharma	116
15	Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer 2015 ·Clinical Cancer Research ·Andreas Varkaris, Paul G. Corn, Nila U. Parikh, Eleni Efstathiou, Jian H. Song, Yu-Chen Lee, Ana M. Aparicio, Anh Hoang, Sanchaika Gaur, (unknown), Sankar N. Maity, (unknown), Bogdan Czerniak, Yiping Shao, Mian M. Alauddin, Sue-Hwa Lin, Christopher J. Logothetis, Gary E. Gallick	37
16	Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers 2015 ·Clinical Cancer Research ·Ana M. Aparicio, Li Shen, Elsa Li Ning Tapia, Jing‐Fang Lu, Hsiang-Chun Chen, Jiexin Zhang, Guanglin Wu, Xuemei Wang, Patricia Troncoso, Paul G. Corn, Timothy C. Thompson, Bradley M. Broom, Keith Baggerly, Sankar N. Maity, Christopher J. Logothetis	192
17	Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer 2015 ·Cancer Research ·Yu-Chen Lee, Song-Chang Lin, Guoyu Yu, Chien-Jui Cheng, Bin Liu, Hsuan‐Chen Liu, David H. Hawke, Nila U. Parikh, Andreas Varkaris, Paul G. Corn, Christopher J. Logothetis, Robert L. Satcher, Li‐Yuan Yu‐Lee, Gary E. Gallick, Sue-Hwa Lin	36
18	Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer 2013 ·Clinical Cancer Research ·Ana M. Aparicio, Andrea Harzstark, Paul G. Corn, Sijin Wen, John C. Araujo, Shi‐Ming Tu, Lance C. Pagliaro, Jeri Kim, Randall E. Millikan, Charles J. Ryan, Nizar M. Tannir, Amado J. Zurita, Paul Mathew, Wadih Arap, Patricia Troncoso, Peter F. Thall, Christopher J. Logothetis	311
19	Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma 2009 ·Journal of Clinical Oncology ·Eric Jonasch, Christopher G. Wood, Surena F. Matin, Shi‐Ming Tu, Lance C. Pagliaro, Paul G. Corn, Ana M. Aparicio, Pheroze Tamboli, Randall E. Millikan, Xuemei Wang, John C. Araujo, Wadih Arap, Nizar M. Tannir	136
20	Amphibian research and monitoring initiative: concepts and implementation 2005 ·Scientific investigations report ·Paul G. Corn, Michael J. Adams, William A. Battaglin, Alisa L. Gallant, (unknown), Melinda G. Knutson, Catherine A. Langtimm, John R. Sauer	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact